NIH RFA · NCATS · R21
RFA-TR-25-002: Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the…
- NOFO number
- RFA-TR-25-002
- Type
- RFA
- Activity code
- R21
- Primary institute
- NCATS · National Center for Advancing Translational Sciences
- Clinical trials
- Not Allowed
- Posted
- Dec 6, 2024
- Opens
- May 2, 2025
- Expires
- Jun 3, 2027
Projects funded under RFA-TR-25-002
NIH RePORTER lists 8 projects funded under RFA-TR-25-002 in FY2022–FY2026, with $3.6M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
8
Distinct projects, FY2022–FY2026
New awards
8
Type 1 (new project) award records
NIH funding
$3.6M
Award dollars under RFA-TR-25-002, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 8 | 8 | $3.6M |
Institutions with the most funding
- Icahn School of Medicine at Mount Sinai$462K · 1 project
- UT Southwestern Medical Center$457K · 1 project
- Columbia University Health Sciences$451K · 1 project
- Children's Mercy Hosp (Kansas City, Mo)$450K · 1 project
- Oregon Health & Science University$448K · 1 project
- University of Minnesota$440K · 1 project
- Stanford University$427K · 1 project
- University of Georgia$415K · 1 project
Funding institutes
- NCATS$3.6M · 8
Activity codes funded
- R218 records
Most recent new awards
- Engineered Treg therapy for pediatric Crohn's disease. (opens NIH RePORTER)
Stanford University · 1R21TR005511-01A1 · NCATS · Notice Jun 5, 2026
$427KR21
- Preclinical Evaluation of Nervonic Acid as a Preventive Therapy for Cerebral Demyelination in Adrenoleukodystrophy (opens NIH RePORTER)
University of Minnesota · 1R21TR006184-01 · NCATS · Notice May 29, 2026
$440KR21
- Investigating Revumenib for Targeted Epigenetic Therapy in Pulmonary Arterial Hypertension (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1R21TR006197-01 · NCATS · Notice May 1, 2026
$462KR21
- AAV9fyhr gene replacement therapy for PDHA1 deficiency in the E75A mouse model (opens NIH RePORTER)
UT Southwestern Medical Center · 1R21TR006182-01 · NCATS · Notice May 1, 2026
$457KR21
- Assessment of Everolimus as a Therapy for Vici Syndrome in a Preclinical Model (opens NIH RePORTER)
Children's Mercy Hosp (Kansas City, Mo) · 1R21TR005180-01A1 · NCATS · Notice Apr 28, 2026
$450KR21
- Repurposing the PI3Kα inhibitor Alpelisib for the treatment of Multiple Hereditary Exostoses (opens NIH RePORTER)
University of Georgia · 1R21TR005505-01A1 · NCATS · Notice Apr 27, 2026
$415KR21
What its predecessor RFA-TR-24-023 funded
RFA-TR-25-002 reissues RFA-TR-24-023. Its funding history is the best guide to who wins under this program: 6 projects and $2.6M in FY2022–FY2026.
Projects funded
6
Distinct projects, FY2022–FY2026
New awards
6
Type 1 (new project) award records
NIH funding
$2.6M
Award dollars under RFA-TR-24-023, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 6 | 6 | $2.6M |
| FY2026 | 0 | 0 | $0 |
Institutions with the most funding
- Children's Hosp of Philadelphia$490K · 1 project
- Northwestern University$440K · 1 project
- Stanford University$427K · 1 project
- Clemson University$419K · 1 project
- University of Florida$419K · 1 project
- Nostopharma, LLC$408K · 1 project
Funding institutes
- NCATS$2.6M · 6
Activity codes funded
- R216 records
Most recent new awards
- Development of anti-LTBP4 as a biologic to treat Limb Girdle Muscular Dystrophy 2C (opens NIH RePORTER)
Northwestern University · 1R21TR005472-01 · NCATS · Notice Jul 24, 2025
$440KR21
- Optimization and Preclinical Validation of QTE Therapy for Friedreich's Ataxia (opens NIH RePORTER)
University of Florida · 1R21TR005475-01 · NCATS · Notice Jul 7, 2025
$419KR21
- Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva (opens NIH RePORTER)
Nostopharma, LLC · 1R21TR005159-01A1 · NCATS · Notice Jul 3, 2025
$408KR21
- Src Homology and Collagen (Shc) inhibition for the treatment of transplant-related pulmonary fibrosis. (opens NIH RePORTER)
Stanford University · 1R21TR005507-01 · NCATS · Notice Jul 2, 2025
$427KR21
- RepSox and its analog for prophylactic intervention in RUNX1 haploinsufficiency FPDMM (opens NIH RePORTER)
Children's Hosp of Philadelphia · 1R21TR005192-01A1 · NCATS · Notice Jun 4, 2025
$490KR21
- Optimization of delivery of HEX for treatment of primary amebic encephalitis (opens NIH RePORTER)
Clemson University · 1R21TR005502-01 · NCATS · Notice May 29, 2025
$419KR21
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under RFA-TR-25-002. Contact the program officer at the institute that fits your research before applying.
- NCATS · National Center for Advancing Translational Sciences
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission - Resubmission of Applications submitted to RFA-TR-23-016, RFA-TR-24-023 and this NOFO The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- The combined budget for direct costs for the two-year project period may not exceed 275,000. No more than 200,000 may be requested in any single year. 
- Project period
- The total project period may not exceed 2 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The NIH intends to commit up to 1,200,000 in FY26, contingent upon receiving scientifically meritorious applications. 3-5 awards are anticipated from this solicitation. Future year amounts will depend on annual appropriations.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-TR-24-023.
Other open NOFOs for R21
- PAR-25-450Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)NCATS · next due Feb 17, 2027
- PAR-25-442Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)NCATS · next due Feb 17, 2027
- PA-25-304NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)NIH · next due Oct 16, 2026
- PAR-25-068Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)NIDDK · next due Oct 16, 2026
- PAR-25-357NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)NEI · next due Oct 16, 2026
- PA-25-306NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)NIH · next due Oct 16, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.